The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, …

DOSING & MONITORING GUIDE INDICATIONS1 Crohn’s Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn’s disease in adults. Ulcerative Colitis: …

Jul 22, 2024 · These 2 randomized clinical trials compare the efficacy and safety of risankizumab vs placebo during an induction trial and a maintenance trial in patients with ulcerative colitis.

Jun 20, 2024 · Ulcerative colitis patients may experience some serious side effects with Skyrizi, including severe allergic reactions, an increased risk of infections, and liver problems.

Jul 23, 2024 · Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulcers on the inner lining of the colon (large intestine).

Jun 18, 2024 · The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach …

For the treatment of Crohn’s disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks). Interrupt treatment with SKYRIZI if drug-induced …

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This …

Nov 28, 2025 · Potential Positives SKYRIZI® received positive reimbursement recommendations from Canada’s Drug Agency, enhancing access to treatment for ulcerative colitis for many …

Jun 20, 2024 · Skyrizi blocks interleukin-23, a cytokine involved in inflammatory processes and is thought to be linked to a number of chronic immune-mediated diseases. It is the first IL-23 …